Mainz Biomed B.V. (MYNZ)
Automate Your Wheel Strategy on MYNZ
With Tiblio's Option Bot, you can configure your own wheel strategy including MYNZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MYNZ
- Rev/Share 0.9233
- Book/Share 6.2449
- PB 0.2242
- Debt/Equity 0.541
- CurrentRatio 1.3184
- ROIC -1.9286
- MktCap 5340794.0
- FreeCF/Share -17.914
- PFCF -0.3079
- PE -0.0626
- Debt/Assets 0.2471
- DivYield 0
- ROE -22.6965
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MYNZ | Maxim Group | -- | Buy | -- | $14 | Feb. 14, 2025 |
News
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and MAINZ, Germany, May 16, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed Expands into Switzerland with labor team w
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Read More
About Mainz Biomed B.V. (MYNZ)
- IPO Date 2021-11-05
- Website https://mainzbiomed.com
- Industry Medical - Diagnostics & Research
- CEO Guido Baechler
- Employees 19